Skip to content

Efficacy evaluation and mechanism study of Houpu Mahuang decoction, Linggui Zhugan decoction and Mahuang decoction in improving the control rate of chronic duration of asthma

Efficacy evaluation and mechanism study of Houpu Mahuang decoction, Linggui Zhugan decoction and Mahuang decoction in improving the control rate of chronic duration of asthma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074735
Enrollment
Unknown
Registered
2023-08-15
Start date
2023-08-15
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

test team :Houpu Mahuang Decoction, Linggui Shugan Decoction, Mahuang Decoction Granule
control group :Houpu Mahuang Decoction, Linggui Zhugan Decoction and Mahuang Decoction were combined with placebo

Sponsors

The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients who meet the diagnostic criteria for chronic duration of bronchial asthma; (2) Patients who meet the criteria of TCM syndrome diagnosis of bronchial asthma with external cold and internal drink syndrome; (3) Age =18 years and =80 years; (4) Did not participate in other clinical studies within one month before being selected; (5) Participate in the research voluntarily and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Pregnant and lactating women; (2) Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, cardiac function grade 3 or above, stroke, cerebral hemorrhage, etc.); (3) Complicated with severe liver and kidney diseases (severe liver diseases refer to cirrhosis, portal hypertension and varicose bleeding, and severe kidney diseases include dialysis and kidney transplantation); (4) Patients with bronchiectasis, tuberculosis, pulmonary embolism or other severe respiratory diseases; (5) serious cognitive and mental disorders; (6) Those who are participating in other clinical trials within one month before being selected; (7) Patients who are allergic to known test drugs.

Design outcomes

Primary

MeasureTime frame
Asthma control test rate ;Number of acute attacks ;

Secondary

MeasureTime frame
Severity and hospitalization rate of acute asthma attack ;Dose of drug use ;pulmonary function ;fractional exhaled nitric oxide, feno ;Induced sputum inflammation phenotype ;eosinophil count ;Inflammation and immune factors ;Asthma control questionnaire ;Asthma quality of life score ;

Countries

China

Contacts

Public ContactLi Suyun

The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

lisuyun2000@126.com+86 139 3841 5502

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026